CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

02nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

Investors Domain

10/07/2020

Information

Cheplapharm announces that it is in advanced negotiations to acquire additional marketing authorizations and intellectual properties for additional territory not yet owned by us for one of our…


more chevron_right
Investors Domain

10/04/2020

CHEPLAPHARM Arzneimittel GmbH Announces Offering

CHEPLAPHARM Arzneimittel GmbH Announces Offering of €1,000,000,000 (equivalent) Senior Secured Notes due 2028


more chevron_right
Investors Domain

09/09/2020

Once again CHEPLAPHARM proves its M&A competence

Cheplapharm announces the acquisition of two product portfolios from LeoPharma and Takeda


more chevron_right
Investors Domain Archive

06/22/2020

CHEPLAPHARM acquires two product portfolios

Greifswald, 06/22/2020


more chevron_right
Archive Investors Domain

06/22/2020

CHEPLAPHARM acquires two product portfolios

Greifswald, 06/22/2020


more chevron_right
Archive

05/15/2020

CHEPLAPHARM wins again

Greifswald, 05/15/2020 – The family-owned pharmaceutical company CHEPLAPHARM Arzneimittel GmbH got honoured with the highly coveted 'Axia Best Managed Companies Award' for the second time in a row.…


more chevron_right
Investor Relations

04/06/2020

CHEPLAPHARM - Quarterly Update Call Q4 / FY 2019

Cheplapharm Arzneimittel GmbH - Quarterly Update Call Q4 / FY 2019 | Wednesday, 08 April 2020, 10:30 BST | 11:30 CEST


more chevron_right
Archive

03/30/2020

Corona Virus (COVID-19) Impact on CHEPLAPHARM activities

Due to the COVID-19 situation, CHEPLAPHARM Arzneimittel GmbH is closely monitoring the potential impact on the various Supply Chains and is committed to keep a transparent approach to all involved …


more chevron_right
Archive

02/13/2020

CHEPLAPHARM moves into new building and issues inaugural bond

Almost a year after the topping-out ceremony in March 2019, the extension at the companies headquarters in Greifswald (Ziegelhof) is ready for occupancy; the employees are now gradually moving to the…


more chevron_right
Archive

01/31/2020

CHEPLAPHARM buys the rights for Seroquel® and Seroquel XR® in Europe (excluding the UK) and North America

Greifswald, 01/31/2020 – AstraZeneca and CHEPLAPHARM have agreed to transfer the commercial rights for SEROQUEL® and other related brands for the North American and the European Market (excluding the…


more chevron_right

Investor Relations topics

Back to top expand_less